Companies: Tenaya Therapeutics
Drugs: TN-201
Tenaya Therapeutics to Present TN-201 Gene Therapy Data for HCM on June 3, 2026
Tenaya Therapeutics is set to release interim data from its TN-201 gene therapy trial for hypertrophic cardiomyopathy (HCM) on June 3, 2026. This data from the MyPEAK-1 study will offer insights into the potential of TN-201, an investigational AAV9 gene therapy targeting the MYBPC3 gene.
Executive Summary
- Tenaya Therapeutics will announce new interim data from the MyPEAK-1 Phase 1b/2 trial (NCT05836259) of TN-201 for adults with MYBPC3-associated HCM on Wednesday, June 3, 2026, via webcast beginning at 8:00 a.m. ET.
- Tenaya has flagged the MyPEAK-1 interim readout as a top strategic priority for the first half of 2026 , underscoring its importance to pipeline valuation and partnership prospects.
- Initial first-in-human results demonstrated feasibility, tolerability, and early evidence of protein expression , supporting the biological rationale for continued development.
- The June 3 data will cover patients from MyPEAK-1 Cohorts 1 and 2, offering a look at dose-response trends and durability of effect in a one-time infusion regimen.
- TN-201 is one of several clinical-stage candidates in Tenaya's cardiovascular gene therapy pipeline, which also includes TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | high |
| Investment | medium |
Ask about this article
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Tenaya Therapeutics to Present TN-201 Gene Therapy Data for HCM on June 3, 2026
Tenaya Therapeutics is set to release interim data from its TN-201 gene therapy trial for hypertrophic cardiomyopathy (HCM) on June 3, 2026. This data from the MyPEAK-1 study will offer insights into the potential of TN-201, an investigational AAV9 gene therapy targeting the MYBPC3 gene. The readout represents a pivotal catalyst for the company's cardiovascular gene therapy platform — and a signal event for analysts tracking one-time gene replacement approaches in a market increasingly defined by chronic small-molecule competition.
Key Takeaways
- Tenaya Therapeutics will announce new interim data from the MyPEAK-1 Phase 1b/2 trial (NCT05836259) of TN-201 for adults with MYBPC3-associated HCM on Wednesday, June 3, 2026, via webcast beginning at 8:00 a.m. ET.
- Tenaya has flagged the MyPEAK-1 interim readout as a top strategic priority for the first half of 2026, underscoring its importance to pipeline valuation and partnership prospects.
- Initial first-in-human results demonstrated feasibility, tolerability, and early evidence of protein expression, supporting the biological rationale for continued development.
- The June 3 data will cover patients from MyPEAK-1 Cohorts 1 and 2, offering a look at dose-response trends and durability of effect in a one-time infusion regimen.
- TN-201 is one of several clinical-stage candidates in Tenaya's cardiovascular gene therapy pipeline, which also includes TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
What Is TN-201 and How Does It Work?
TN-201 is an investigational gene therapy that uses an adeno-associated virus serotype 9 (AAV9) capsid to deliver a working copy of the MYBPC3 gene directly to heart muscle cells. Mutations in MYBPC3 prevent cardiac cells from producing adequate levels of myosin-binding protein C, a protein essential for normal heart contraction and relaxation. The result is hypertrophic cardiomyopathy — a condition characterized by abnormal thickening of the heart muscle that can lead to arrhythmias, heart failure, and sudden cardiac death.
Rather than managing symptoms with beta-blockers, calcium channel blockers, or invasive septal reduction procedures, TN-201 aims to correct the underlying genetic defect in a single infusion. The AAV9 capsid has been used in gene therapies administered to thousands of patients globally, providing a well-characterized delivery platform. In the context of HCM, this approach represents a fundamentally different therapeutic hypothesis: replace the missing protein at the genetic source rather than modulate downstream physiology.
The TN-201 clinical program is being evaluated in the MyPEAK-1 Phase 1b/2 study (NCT05836259), which enrolled adult patients with MYBPC3-associated HCM. Six patients were treated across the initial phase — three received a lower dose in the first cohort, with subsequent cohorts exploring higher doses. First-in-human results published from MyPEAK-1 showed that TN-201 treatment was feasible and safe, with early evidence of protein expression supporting the biological rationale for continued development. SEC filings confirm that TN-201 and TN-401 constitute the company's clinical-stage cardiovascular gene therapy candidates.
Why Does the June 3 Data Matter for Competitive Positioning?
The upcoming readout arrives at a moment of heightened activity in the HCM therapeutic space. Bristol-Myers Squibb's mavacamten secured FDA approval as the first cardiac myosin inhibitor for obstructive HCM, establishing a new standard of care and a commercial benchmark. Cytokinetics' aficamten is advancing through late-stage development. Against this backdrop of small-molecule competition, TN-201 represents a structurally distinct modality — one-time gene replacement versus chronic oral therapy.
For business development teams evaluating the cardiovascular gene therapy pipeline, the June 3 data will answer several critical questions. First, does TN-201 demonstrate dose-dependent protein expression across Cohorts 1 and 2? Second, are there signals of clinical benefit — reductions in left ventricular wall thickness, improvements in diastolic function, or decreases in NT-proBNP — that would support advancement to a registrational trial? Third, does the safety profile remain manageable, particularly regarding the immune response to AAV9 and potential cardiac inflammation risks that have shadowed other AAV-based programs?
Investors and strategists should also monitor the webcast's framing of next steps. If Tenaya signals plans for a registrational pathway — potentially an End-of-Phase 2 meeting with the FDA — that would materially de-risk the program and open partnership or financing conversations. Conversely, if the data reveal durability concerns or safety signals at higher doses, competitors with chronic dosing small molecules could see their competitive moat reinforced.
What Should Analysts Watch For on June 3?
Beyond the topline safety and protein expression data, several secondary endpoints will shape the market's interpretation. Cardiac MRI measurements of myocardial mass and fibrosis, exercise capacity assessments via cardiopulmonary testing, and biomarker trends (particularly NT-proBNP and troponin) will provide a more complete picture of whether TN-201 is delivering meaningful clinical impact beyond target engagement.
The patient follow-up duration will also matter. Gene therapy durability is a central question for AAV-based programs — early protein expression is encouraging, but sustained expression over 12 to 24 months is what regulators, payors, and clinicians will ultimately require. If the June 3 data include patients with 12 or more months of follow-up, that will carry outsized weight in shaping expectations.
Finally, watch for any commentary on manufacturing scalability and commercial readiness. AAV9 gene therapies face well-documented challenges in production cost and supply chain complexity. Tenaya's ability to articulate a credible path to commercial-scale manufacturing will influence both partnership interest and long-term valuation models.
Frequently Asked Questions
What is TN-201?
TN-201 is an investigational gene therapy developed by Tenaya Therapeutics. It uses an AAV9 capsid to deliver a functional MYBPC3 gene to cardiac muscle cells, designed to address the underlying genetic cause of hypertrophic cardiomyopathy in patients with MYBPC3 mutations. Changes in the MYBPC3 gene prevent certain cells from making a protein needed for the heart to pump as expected, and TN-201 is designed to restore that function through a one-time intravenous infusion.
What is the gene therapy for HCM?
TN-201 is an investigational gene therapy for hypertrophic cardiomyopathy that targets MYBPC3 mutations. It uses an AAV9 capsid — a delivery vehicle that has been used to treat thousands of patients globally with various gene therapies — to reach the specific cardiac muscle cells responsible for heart contraction and relaxation.
What is the MyPEAK-1 trial?
The MyPEAK-1 trial (NCT05836259) is a Phase 1b/2 study evaluating the safety, tolerability, and preliminary efficacy of TN-201 in adult patients with MYBPC3-associated hypertrophic cardiomyopathy. The trial includes multiple dose cohorts and is designed to establish proof of concept for AAV9-mediated gene replacement in this indication.
When will the TN-201 clinical trial data be presented?
Tenaya Therapeutics will announce new interim data from the MyPEAK-1 trial on Wednesday, June 3, 2026, via a webcast beginning at 8:00 a.m. ET. The data will include results from Cohorts 1 and 2 of the TN-201 clinical trial program.
What are the strategic implications of the TN-201 readout?
The June 3 data will serve as a critical catalyst for Tenaya's pipeline valuation, partnership potential, and competitive positioning in the HCM space. Positive results — particularly evidence of dose-dependent protein expression and a manageable safety profile — would strengthen TN-201's case as a first-in-class gene replacement therapy and differentiate it from chronic small-molecule competitors like mavacamten.
Related profiles
Related coverage
This article follows our editorial standards. Report a correction via editorial contact.
